SERA (Sera Prognostics) Cash And Cash Equivalents : $2.68 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Sera Prognostics Cash And Cash Equivalents?

Sera Prognostics's quarterly cash and cash equivalents increased from Mar. 2024 ($4.24 Mil) to Jun. 2024 ($4.66 Mil) but then stayed the same from Jun. 2024 ($4.66 Mil) to Sep. 2024 ($2.68 Mil).

Sera Prognostics's annual cash and cash equivalents declined from Dec. 2021 ($58.93 Mil) to Dec. 2022 ($29.88 Mil) and declined from Dec. 2022 ($29.88 Mil) to Dec. 2023 ($3.88 Mil).

Sera Prognostics Cash And Cash Equivalents Historical Data

The historical data trend for Sera Prognostics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sera Prognostics Cash And Cash Equivalents Chart

Sera Prognostics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

21.39

13.53

58.93

29.88

3.88

Sera Prognostics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash And Cash Equivalents	Get a 7-Day Free Trial															9.66	3.88	4.24	4.66	2.68

Sera Prognostics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Sera Prognostics (NAS:SERA) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Sera Prognostics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Sera Prognostics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Sera Prognostics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sera Prognostics Inc (NAS:SERA) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

2749 East Parleys Way, Suite 200, Salt Lake City, UT, USA, 84109

Website

https://www.seraprognostics.com

Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.

Executives

Austin Aerts	officer: Chief Financial Officer	2479 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
John J. Boniface	officer: Chief Scientific Officer	C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Paul Kearney	officer: Chief Data Officer	2749 E. PARLEYS WAY, C/O SERA PROGNOSTICS, INC., SALT LAKE CITY UT 84109
Mansoor Raza Mirza	director	C/O KARYOPHARM THERAPEUTICS INC., 2 MERCER ROAD, NATICK MA 01760
Benjamin Jackson	officer: General Counsel	320 WAKARA WAY, SALT LAKE CITY UT 84108
Robert Gardner Harrison	officer: Chief Information Officer	320 WAKARA WAY, SALT LAKE CITY UT 84108
Zhenya Lindgardt	director	C/O SERA PROGNOSTICS INC, 2749 EAST PARLEYS WAY SUITE 200, SALT LAKE CITY UT 84109
Jane F Barlow	director	6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Michael R Foley	officer: Chief Medical Officer	C/O SERA PROGNOSTICS INC, 2749 EAST PARLEYS WAY SUITE 200, SALT LAKE CITY UT 04109
Sandra Aj Lawrence	director	C/O EVERGY, INC., 1200 MAIN STREET, KANSAS CITY MO 64105
Gregory C Critchfield	director, officer: Chief Executive Officer	320 WAKARA WAY, SALT LAKE CITY UT 84108
Jay M Moyes	officer: Chief Financial Officer
Blue Ox Healthcare Partners Sp, Llc	10 percent owner	135 E. 57TH STREET, 23RD FLOOR, NEW YORK NY 10022
Bxhcp Sp Ii, Llc	10 percent owner	135 E 57TH STREET, 23RD FLOOR, NEW YORK NY 10022
Bxhcp Sp Iii, Llc	10 percent owner	229 DAWSON ROAD, HILLSDALE NY 12529